Drug Self-Administration Markets to 2014

Devices, Drugs, Product Strategies and Forecasts

Weekly Newsletter

Greystone Research
associates

Drug Self-Administration Markets to 2014

Greystone Research Associates is pleased to announce the publication of a new market study. Drug Self-Administration Markets to 2014: Devices, Drugs, Strategies and Forecasts is a comprehensive evaluation and analysis of the technology, products demographics, prescribing trends, and participants providing the driving force behind this evolving segment of the drug delivery sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for self-administration of non-oral drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Evolving Technology and Tailored Delivery Devices While alternative methods for delivering therapeutics to patients have had some notable successes, most drugs continue to be delivered orally. Because they cannot tolerate the first-pass metabolism of the digestive tract, the recent escalation in new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery technologies. Now a number of factors are converging to create both risk and opportunity for drug makers and their delivery device partners. These include new classes of drugs for previously refractory conditions, the growing trend toward self-administration for chronic diseases, shifting patient demographics in industrial countries, caregiver safety legislation, and continued pressure to control healthcare costs. These factors are giving rise to a new generation of sophisticated, application-specific injection, inhalation and transdermal drug products designed to satisfy caregiver and patient preferences while addressing managed care initiatives and the formulation limitations of new classes of therapeutic drugs. Because of their ability to safely and reliably satisfy treatment protocols and compliance goals, nonoral drug delivery products will have a significant impact on the future of drug self-administration.

Managed Care Managers Management Consultants Financial Analysts

Pharma Product Managers Device Suppliers Biotech Managers Product Developers Component Suppliers CMOs, CSOs Drug Marketers & Strategists Clinical Managers Drug Distributors Pharma Regulators

Drug Delivery Ecosystem

Industry Hierarchical Chain

Table of Contents
Executive Summary Drug Market Dynamics
Evolving Drug Market Factors Evolving Models of Disease and Human Health Chronic Disease and Self-administration Managed Care and Prescribing Trends Drug Self-Administration Demand Factors Shifting Patient Demographics Biological Drug Proliferating Delivery Device Technology & Evolving Patient Expectations

Drug Self-Administration Product Segments and Market Drivers

Injectable Drug Self-Administration Products
Market Sector Dynamics The Shift to Prefilled Devices Device Selection Factors Market Segmentation & Cost Product Features & Ease of Use Custom Device Designs & Branding Prefilled Syringes (PFS) Glass PFS Plastic PFS Prospects for Autoinjector s Key PFS Therapeutic Segments The Top Ten PFS Drug Products Five Segments Driving PFS Growth The PFS Supply Chain Technology Leaders Evolving Device Innovations The Competitive Landscape PFS Supplier Profiles Pen Injectors Reusable Pens Disposable Pens Key Pen Injector Therapeutic Segments The Top Ten Pen Injector Drug Products Five Segments Driving Pen Injector Growth Pen Injector Company Profiles Needle-free Injectors (NFI) Reusable NFI Disposable Competitive NFI Therapeutic Segments Needle-free Company Profiles

Inhaled Drug Self-Administration Products

Market Sector Dynamics The Upper Respiratory Market Established Therapeutic Targets Dual Drug Inhalers The Systemic/Deep Lung Market Established Markets Emerging Therapies Inhaler Technology and Market Prospects Inhaler Product Segments Dry Powder Inhalers Device Design Factors Powder Technology Packaging Issues

Inhaled Drug Self-Administration Products (contd)

Key DPI Therapeutic Markets The Top Ten DPI Drug Products Five Segments Driving DPI Growth DPI Device Company Profiles Metered Dose Inhalers Basic Designs Breathe Actuated Designs Key MDI Therapeutic Markets MDI Device Company Profiles Nebulizers Established Nebulizer Therapies Evolving Nebulizer Technology Nebulizer Device Company Profiles Performance Factors Bioavailability Dose Reproducibility Active Compound Stability

Transdermal Drug Products

Market Sector Dynamics Traditional Patch Markets Emerging Markets Transdermal Patch Market Drivers Prescription Patch Design & Technology Passive Patch Architecture Passive Transdermal Patch Design Passive Patch Construction Active Transport Patch Technologies Electrical Current Iontophoresis Electroporation Microporation Laser Ablation Mechanical Arrays Radio Frequency Thermal/Heat Ultrasound Prescription Patch Development Factors Key Transdermal Therapeutic Markets The Top Ten Transdermal Drug Products Segments Driving Transdermal Growth Transdermal Product Company Profiles

Drug Self-Administration Therapeutic Sector Analysis & Forecasts

ADHD Anticoagulants Arthritis Asthma/COPD Cardiovascular Contraception Cystic Fibrosis Diabetes Hematopoietics Hepatitis Hormone Therapy/Replacement Multiple Sclerosis Neurology Osteoporosis Pain Management Psoriasis Sexual Health

Comprehensive Assessments & Forecasts

Feature Summary
Provides detailed analysis of drug self-administration market segments, market dynamics and market demographics Analyzes therapeutic demand drivers and evaluates commercial drug products in more than two dozen major self-administration therapeutic segments Analyzes design factors, material selection issues, technologies and market development issues for injection devices, inhalation devices and transdermal drug products designed for self-administration Charts product data, market share, and forecasts to 2014 Profiles self-administration drug product and device participants, their product development activities, business strategies, and corporate alliances and affiliations Assesses the importance of pharma-device alliances and design partnerships on drug self-administration commercialization Evaluates the impact of economic, technology, and regulatory factors

Report Format and Availability

This report is available electronic format. A site license for a single physical location and an Enterprise license are also available.

Methodology
Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations. Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations. Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

About Greystone Research Associates

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

How To Order
Ordering Information
Orders may be placed via postal mail, e-mail or fax. Orders not accompanied by a purchase order must contain a telephone number for verification, and clearly indicate the physical shipping address. Orders which are not prepaid must indicate the billing address. There is no charge for handling and shipping for destination addresses within the continental US.

Payment
We accept the following forms of payment: Company Check: Please make checks payable to Greystone Associates Credit Cards: We accept MasterCard, Visa and American Express Wire Transfers: See Wire Transfers below for more information Orders Outside the U.S. Orders must be prepaid via credit card, company check in US funds and drawn on a US bank, or wire transfer. There is a $50 per copy shipping and handling charge for international shipments.

Wire Transfers:

TD Banknorth 300 Franklin Street Manchester, NH 03103 (Call for Account Information)

Mailing Address:

Greystone Associates Client Services P.O. Box 1362 Amherst, NH 03031

Drug Self-Administration Markets to 2014

Select Format Price (U.S. funds) Total

Electronic Site License Enterprise License

$4,850.00 $6,500.00 $8,500.00

Total Payment (U.S. funds)

Method of Payment: ___ Company Check

___

___

___

___ Wire Transfer

(International)

Card Number:___________________________ Name on Card ________________________________________ Expiration Date: ____________ Card CVV_______ Signature___________________________________
Billing Information
Name: Title: Company: Street Address: City,State/Province: Country/Postal Code: Phone: Fax: Email:

Shipping Information Click here if same as Billing Information

Name: Title: Company: Street Address: City,State/Province: Country/Postal Code: Phone: Fax: Email:

98 Route 101A

P .O. Box 1362

Amherst, NH 03031

603-595-4340

(F) 603-804-0466 reports@greystoneassociates.org